Last reviewed · How we verify

Amlodipine High — Competitive Intelligence Brief

Amlodipine High (Amlodipine High) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine High (Amlodipine High) — Handok Inc.. Calcium channel blocker

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amlodipine High TARGET Amlodipine High Handok Inc. phase 2 Calcium channel blocker L-type calcium channels
Amlodipine/Losartan/Chlorthalidone Amlodipine/Losartan/Chlorthalidone Hanmi Pharmaceutical Company Limited marketed Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic) L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter
Nicardipine + Verapamil + Nitroglycerin Nicardipine + Verapamil + Nitroglycerin Peng Roc Chen, MD marketed Combination antihypertensive/antianginal (calcium channel blockers + nitrate) L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin)
irbesartan, amlodipine and hydrochlorothiazide irbesartan, amlodipine and hydrochlorothiazide Assistance Publique - Hôpitaux de Paris marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
Treatment T Treatment T Boryung Pharmaceutical Co., Ltd marketed Calcium channel blocker L-type calcium channels
Nifedipine/Telmisartan Nifedipine/Telmisartan Bayer marketed Calcium channel blocker + Angiotensin II receptor blocker combination L-type calcium channels; AT1 angiotensin II receptor
olmesartan/amlodipine + hydrochlorothiazide, if necessary. olmesartan/amlodipine + hydrochlorothiazide, if necessary. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

  1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
  2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  3. Ain Shams University · 1 drug in this class
  4. Bioprojet · 1 drug in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Handok Inc. · 1 drug in this class
  8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
  9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine High — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-high. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: